Preprint Communication Version 1 Preserved in Portico This version is not peer-reviewed

Strategic Investigation of Ligands for Melanoma Therapy: Docking Analysis and Predictive Toxicity Assessment

Version 1 : Received: 3 December 2023 / Approved: 4 December 2023 / Online: 5 December 2023 (04:39:27 CET)

How to cite: Ferrari, I. V. Strategic Investigation of Ligands for Melanoma Therapy: Docking Analysis and Predictive Toxicity Assessment. Preprints 2023, 2023120211. https://doi.org/10.20944/preprints202312.0211.v1 Ferrari, I. V. Strategic Investigation of Ligands for Melanoma Therapy: Docking Analysis and Predictive Toxicity Assessment. Preprints 2023, 2023120211. https://doi.org/10.20944/preprints202312.0211.v1

Abstract

For the first time, this study identified seven potential ligands with high binding energies through the docking approach against the Crystal Structure of human Melanoma-associated antigen B1 (MAGEB1). The ligands—Imatinib, Bafatinib, Diosmin, Ginkgetin, Bilobetin, Amentoflavone, and Hypericin—showing strong binding energies around -10 kcal/mol, indicate a potentially robust interaction with the target protein. Moreover, the additional step of predicting toxicity properties using the pKCSM server provides valuable insights into the safety profiles of these ligands. From these results, the parameters for Diosmin: —Max. tolerated dose (human),- Oral Rat Acute Toxicity (LD50), and - Oral Rat Chronic Toxicity (LOAEL)—suggest a favorable safety profile, making it a potential candidate for further consideration against Melanoma. Moving forward, it's advisable to conduct further experimental validations, including in vitro and in vivo studies, to confirm the efficacy and safety of Diosmin and other potential ligands. Consideration of pharmacokinetics, metabolism, and specific mechanisms of action will contribute to a comprehensive understanding of these compounds' potential as therapeutic agents.

Keywords

 Melanoma; pKCSM;Docking approach; Diosmin;MAGEB1

Subject

Public Health and Healthcare, Primary Health Care

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.